CD40LG and COVID-19: As was the case for AfuLy stimulation, frequencies of background-corrected CD154+ RarLy-reactive Th cells (median 0.13% vs. 0.09%, Figure S6A) and their phenotypes (Figure S6B) did not differ significantly in COVID-19 patients and controls.